See more : Chiyoda Integre Co.,Ltd. (6915.T) Income Statement Analysis – Financial Results
Complete financial analysis of Telo Genomics Corp. (TELO.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Telo Genomics Corp., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Yangtze Optical Fibre And Cable Joint Stock Limited Company (601869.SS) Income Statement Analysis – Financial Results
- M.T.I Wireless Edge Ltd. (MWE.L) Income Statement Analysis – Financial Results
- CanaFarma Hemp Products Corp. (CNFA.CN) Income Statement Analysis – Financial Results
- Ryanair Holdings plc (RY4C.IR) Income Statement Analysis – Financial Results
- Elmos Semiconductor SE (ELG.DE) Income Statement Analysis – Financial Results
Telo Genomics Corp. (TELO.V)
About Telo Genomics Corp.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.54K | 33.11K | 56.96K | 62.23K | 64.72K | 82.91K | 124.33K | 110.36K | 74.09K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -39.54K | -33.11K | -56.96K | -62.23K | -64.72K | -82.91K | -124.33K | -110.36K | -74.09K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.32M | 1.36M | 1.12M | 603.90K | 364.74K | 196.77K | 1.54M | 1.12M | 98.62K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 1.46M | 986.63K | 653.30K | 946.12K | 856.75K | 3.07M | 0.00 | 73.49K | 111.85K | 31.18K | 98.29K |
| Selling & Marketing | 0.00 | 86.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.35M | 1.46M | 986.63K | 653.30K | 946.12K | 856.75K | 3.07M | 8.18M | 73.49K | 111.85K | 31.18K | 98.29K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 183.48K | 95.70K | 0.00 | 11.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.68M | 2.82M | 2.11M | 1.26M | 1.31M | 1.05M | 4.61M | 9.30M | 73.49K | 111.85K | 31.18K | 98.29K |
| Cost & Expenses | 2.72M | 2.82M | 2.11M | 1.26M | 1.31M | 1.05M | 4.61M | 9.30M | 73.49K | 111.85K | 31.18K | 98.29K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.44K | 3.12K | 8.52K | 4.74K |
| Interest Expense | 4.61K | 5.21K | 5.39K | 0.00 | 26.54K | 20.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 39.54K | 33.11K | 56.96K | 62.23K | 64.72K | 82.91K | 124.33K | 110.36K | 74.09K | 0.00 | 29.06K | 49.35K |
| EBITDA | -2.67M | -2.78M | -2.05M | -1.01M | -1.15M | -970.61K | -4.48M | -9.79M | -1.65M | -315.19K | -16.65K | -73.62K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.72M | -2.82M | -2.11M | -1.07M | -1.22M | -1.05M | -4.50M | -9.30M | -73.49K | -111.85K | -45.71K | -122.97K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.39K | -5.21K | 40.04K | 182.61K | 69.16K | -20.67K | -23.19K | -613.02K | -33.80K | -289.14K | 8.52K | 4.74K |
| Income Before Tax | -2.71M | -2.82M | -2.11M | -1.07M | -1.24M | -1.07M | -4.69M | -9.91M | -70.05K | -108.73K | -37.19K | -118.23K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 10.00K | -5.20K | -5.39K | 183.48K | 122.23K | -78.23K | 98.54K | 613.02K | -74.09K | 0.00 | -23.05K | -29.42K |
| Net Income | -2.71M | -2.82M | -2.11M | -1.07M | -1.24M | -1.07M | -4.69M | -9.91M | -70.05K | -108.73K | -37.19K | -118.23K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.05 | -0.04 | -0.02 | -0.04 | -0.08 | -0.08 | -0.21 | -0.02 | -0.03 | -0.01 | -0.03 |
| EPS Diluted | -0.04 | -0.05 | -0.04 | -0.02 | -0.04 | -0.08 | -0.08 | -0.21 | -0.02 | -0.03 | -0.01 | -0.03 |
| Weighted Avg Shares Out | 71.38M | 60.15M | 58.66M | 46.89M | 29.93M | 13.23M | 59.77M | 47.70M | 4.40M | 4.21M | 4.25M | 3.94M |
| Weighted Avg Shares Out (Dil) | 71.38M | 60.15M | 58.66M | 46.89M | 29.93M | 13.23M | 59.77M | 47.70M | 4.40M | 4.21M | 4.25M | 3.94M |
Source: https://incomestatements.info
Category: Stock Reports